Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Semi-parametric models for mismeasured exposure information in vaccine trials.

Golm GT, Halloran ME, Longini IM Jr.

Stat Med. 1998 Oct 30;17(20):2335-52.

PMID:
9819831
2.

Challenges to conducting HIV preventative vaccine trials with adolescents.

McClure CA, Gray G, Rybczyk GK, Wright PF.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):726-33. Review.

PMID:
15167292
3.

Therapeutic vaccine trails in Thailand.

Churdboonchart V.

J HIV Ther. 2004 Sep;9(3):57-9. Review.

PMID:
15534562
4.

Vaccines and vaccine strategies against HIV.

Stratov I, DeRose R, Purcell DF, Kent SJ.

Curr Drug Targets. 2004 Jan;5(1):71-88. Review.

PMID:
14738219
5.

HIV vaccine research in Thailand: lessons learned.

Pitisuttithum P.

Expert Rev Vaccines. 2008 Apr;7(3):311-7. doi: 10.1586/14760584.7.3.311. Review.

PMID:
18393601
6.

HIV-1 prophylactic vaccine trials in Thailand.

Pitisuttithum P.

Curr HIV Res. 2005 Jan;3(1):17-30. Review.

PMID:
15638720
7.

Some important issues in the planning of phase III HIV vaccine efficacy trials.

Boily MC, Mâsse BR, Desai K, Alary M, Anderson RM.

Vaccine. 1999 Feb 26;17(7-8):989-1004. Review.

PMID:
10067708
8.

HIV vaccines in infants and children.

Lambert JS.

Paediatr Drugs. 2005;7(5):267-76. Review.

PMID:
16220994
9.

ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development.

Marovich MA.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S99-104. Review.

PMID:
15285709
10.

The challenges of HIV vaccine development and testing.

Burgers WA, Williamson C.

Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):277-91. Review.

PMID:
15778116
11.

[The quest for an HIV vaccine].

Girard MP.

Bull Acad Natl Med. 2005 May;189(5):831-44; discussion 844. Review. French.

PMID:
16433455
12.

Efficacy and cost-effectiveness of the first generation of HIV prevention interventions for people with severe and persistent mental illness.

Johnson-Masotti AP, Weinhardt LS, Pinkerton SD, Otto-Salaj LL.

J Ment Health Policy Econ. 2003 Mar;6(1):23-35. Review.

PMID:
14578545
13.

Predictive value of primate models for AIDS.

Haigwood NL.

AIDS Rev. 2004 Oct-Dec;6(4):187-98. Review.

PMID:
15700617
14.

Epidemiological considerations in planning HIV preventive vaccine trials.

Esparza J, Burke D.

AIDS. 2001;15 Suppl 5:S49-57. Review. No abstract available.

PMID:
11816175
16.

Statistical issues in the design of HIV vaccine trials.

Schaper C, Fleming TR, Self SG, Rida WN.

Annu Rev Public Health. 1995;16:1-22. Review.

PMID:
7639865
17.

Vaccine development against HIV-1: current perspectives and future directions.

Edgeworth RL, San JH, Rosenzweig JA, Nguyen NL, Boyer JD, Ugen KE.

Immunol Res. 2002;25(1):53-74. Review.

PMID:
11868934
18.

The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.

Fernández-Cruz E, Navarro J, Rodríguez-Sainz C, Gil J, Moreno S, González-Lahoz J, Carbone J.

Expert Rev Vaccines. 2003 Dec;2(6):739-52. Review.

PMID:
14711358
19.
20.

Vaccine trials.

Farrington CP, Miller E.

Mol Biotechnol. 2001 Jan;17(1):43-58. Review.

PMID:
11280930

Supplemental Content

Support Center